These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23631283)

  • 1. [Heart rate reduction due to selective specific inhibition of the If current opens new possibilities in treatment of basic cardiovascular diseases].
    Chichkanov GG; Tsorin IB
    Eksp Klin Farmakol; 2013; 76(2):37-42. PubMed ID: 23631283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
    Reil JC; Reil GH; Böhm M
    Trends Cardiovasc Med; 2009 Jul; 19(5):152-7. PubMed ID: 20005474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversing dobutamine-induced tachycardia using ivabradine increases stroke volume with neutral effect on cardiac energetics in left ventricular post-ischaemia dysfunction.
    Bakkehaug JP; Naesheim T; Torgersen Engstad E; Kildal AB; Myrmel T; How OJ
    Acta Physiol (Oxf); 2016 Oct; 218(2):78-88. PubMed ID: 27145482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivabradine: Current and Future Treatment of Heart Failure.
    Thorup L; Simonsen U; Grimm D; Hedegaard ER
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):89-97. PubMed ID: 28371247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.
    Mulder P; Barbier S; Chagraoui A; Richard V; Henry JP; Lallemand F; Renet S; Lerebours G; Mahlberg-Gaudin F; Thuillez C
    Circulation; 2004 Apr; 109(13):1674-9. PubMed ID: 14981003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivabradine: A Current Overview.
    Guha K; Allen CJ; Hartley A; Sharma R
    Curr Clin Pharmacol; 2016; 11(4):241-249. PubMed ID: 27784216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited role for ivabradine in the treatment of chronic heart failure.
    Cullington D; Goode KM; Cleland JG; Clark AL
    Heart; 2011 Dec; 97(23):1961-6. PubMed ID: 21917660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction.
    Heusch G; Kleinbongard P
    Drugs; 2016 May; 76(7):733-40. PubMed ID: 27041289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ivabradine in patients with stable ischemic heart disease and left ventricular systolic dysfunction: the results of the BEAUTIFUL study].
    Filipovský J
    Vnitr Lek; 2009 May; 55(5):513-6. PubMed ID: 19514618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart rate reduction in heart failure: ivabradine or beta blockers?
    Guglin M
    Heart Fail Rev; 2013 Jul; 18(4):517-28. PubMed ID: 22972475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The efficacy of ivabradine in chronic heart failure (review)].
    Isakadze A; Makharadze T; Gvishiani M
    Georgian Med News; 2015 Apr; (241):44-9. PubMed ID: 25953938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
    Rosano GM; Vitale C; Volterrani M
    Adv Ther; 2010 Apr; 27(4):202-10. PubMed ID: 20495895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart rate and cardiovascular protection.
    Caetano J; Delgado Alves J
    Eur J Intern Med; 2015 May; 26(4):217-22. PubMed ID: 25704330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
    Ferrari R; Ceconi C
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):959-73. PubMed ID: 21878041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N
    Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivabradine: beyond heart rate control.
    Riccioni G; Vitulano N; D'Orazio N
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of ivabradine on left atrial electromechanical function in patients with systolic heart failure.
    Ozturk S; Öztürk S; Erdem FH; Erdem A; Ayhan S; Dönmez İ; Yazıcı M
    J Interv Card Electrophysiol; 2016 Sep; 46(3):253-8. PubMed ID: 27039084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotective effects of the Ιf current inhibition by ivabradine during cardiac dysfunction.
    Su JB
    Curr Pharm Biotechnol; 2014; 14(14):1213-9. PubMed ID: 24831809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.